Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $58.84M | $43.88M | $39.68M | $10.00M | $3.41M | $1.71M |
| Cost of Revenue | $45.24M | $42.59M | $48.27M | N/A | N/A | $45.81M |
| Gross Profit | $13.60M | $1.29M | $-8.59M | $10.00M | $3.41M | $-44.10M |
| Gross Margin | 23.12% | 2.94% | -21.66% | 100.00% | 100.00% | -2577.32% |
| Operating Expenses | $492.61M | $351.35M | $237.13M | $192.78M | $88.03M | $18.34M |
| Operating Income | $-479.00M | $-350.06M | $-245.73M | $-182.78M | $-84.61M | $-62.44M |
| Operating Margin | -814.09% | -797.84% | -619.26% | -1827.75% | -2479.20% | -3649.39% |
| Net Income | $-463.66M | $-328.07M | $-239.48M | $-186.48M | $-87.01M | $-62.52M |
| Net Margin | -788.02% | -747.71% | -603.50% | -1864.79% | -2549.25% | -3654.30% |
| EPS (Basic) | $-1.69 | $-1.58 | $-1.36 | $-1.05 | $-0.52 | $-0.37 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |